

Collaborative Working Agreement Summary

1. Project Name:	Implementing a New Model of Obesity care in Greater Manchester Integrated Care System
2. Organisations involved with this Joint Working Project are:	Eli Lilly & Company (Lilly) Health Innovation Manchester (HInM) hosted by Manchester University NHS Foundation Trust (MFT)
3. The objectives for this project are:	<p>This project aims to support optimisation of the obesity pathway by using results from two previous collaborative working agreements between Health Innovation Manchester (HInM) and Lilly, “Understanding Obesity Care Pathways in Greater Manchester” and “Reimagining Obesity Care Pathways in Greater Manchester”, to implement solutions to improve patient outcomes</p> <p>By utilising the outputs from these 2 previous projects, this project aims to support local weight management service commissioners to implement an alternative, scalable and sustainable approach to the management of eligible patients living with obesity.</p> <p>To maximise the impact of any weight management interventions, there needs to be an effective and efficient obesity service. This project will support redesigning the obesity pathway with an aim to improve patient and system outcomes. The project will also aim to evaluate the system wide impact of weight management support as part of a primary care-based weight management service provision. As part of the project, all types of service capabilities and innovations will be considered, including, but not limited to, digital support and community pharmacists. To support the implementation of the newly designed care model, the project will enlist several GP practices to test and contribute to the co-development of a ProActive Registry Management (PARM) Obesity tool, which enables the identification of patient cohorts for care optimisation through appropriate weight management pathways.</p> <p>This project will be run as a Collaborative Working Agreement (CWA) in line with Clause 20 of the 2024 ABPI Code of Practice. Any benefits realised from the CWA i.e. improved clinic efficiencies will be realised at an organisational level by Health Innovation Manchester</p> <p>No individual healthcare professional will benefit from the implementation of this Agreement.</p>

Collaborative Working Agreement Summary

4. Roles and Responsibilities, including any funding

Lilly UK:

- Initial project scoping, design and planning including co-development of project plans and other core project documents.
- Project management and oversight including stakeholder engagement and management; responsibility for the project plan to ensure completion of milestones within scope, budget and timeframe; communication planning and maintaining project documents
- Approval of Project Initiation Document (PID) and executive summary and development of Agreement in line with ABPI code of practice requirements.
- Pathway redesign/Commissioning model support and co-facilitation of Commissioning model Group Workshop(s) and subsequent write-up
- Support for primary care sites for the implementation, co-development and testing of the PARM Obesity tool
- Support certification and publication of results in appropriate clinical and trade press (draft documentation will be shared any NHS organisations named in publications for approval)
- Stakeholder engagement support and wider implementation planning with strategic bodies such as the ICS and Office for Life Sciences
- Joint publication of project outputs including publication on the Lilly UK corporate website, The ABPI repository and other clinical or trade press.
- At no point during this project will Lilly have access to any patient identifiable data.
- Lilly will have no input into clinical decision-making for patient eligibility, risk or clinical/medication guidelines

Health Innovation Manchester

- Initial project scoping, design and planning including co-development of project plans and other core project documents.
- Responsible for HInM governance process with regards to entering into this agreement
- Understanding of Health Innovation Manchester process for receiving services and funding associated with this Agreement
- Stakeholder management between Health Innovation Manchester, Greater Manchester ICS, Greater Manchester Medicines Management Group
- Identification of primary care sites for the co-development and testing of the PARM Obesity tool. This would entail the selected primary care teams to download a prototype of the tool and share feedback on its utility and functionality at a co-design workshop.
- General project administrative support including prepare agendas and issue notices for meetings; ensure all necessary documents requiring discussion or comment are attached to the agenda, distribute the agenda 2 days prior to the meeting. Take action notes of proceedings and prepare minutes of meeting. Distribute the minutes to all members within 3 working days after the meeting

Collaborative Working Agreement Summary

	<ul style="list-style-type: none"> • Baseline data provision through existing databases (or where applicable the PARM Obesity tool) and / or development of ‘gap’ data collection plan • Clinical and system leadership to stratify patients into eligibility and risk • Clinical and system leadership for pathway redesign and commissioning model • Commissioning support to ensure alignment of new pathway with current service provision • Organisation, management and co-facilitation of Pathway Redesign/Commissioning model Group Meeting(s) • Design and Co-ordinate structured interviews with Health Care Professionals and patients to create HCP and patient feedback reports • Dissemination of results including write up for publication in clinical press (including the impact of using PARM Obesity in primary care) • Provision of relevant and appropriate Health Care Professionals, managerial and administrative staff to attend workshops and provision of remuneration if required <p>Financial details Total Project Cost: £432,240</p> <p>Lilly: £180,000 funding paid directly to Manchester University NHS Foundation Trust on behalf of Health Innovation Manchester Lilly Staff and resource: £35,145 Health Innovation Manchester Staff and resource: £216,705</p>
5. The expected benefits for patients on delivery of this project are:	Collaborative working – As a minimum the current standard of patient care will be maintained. It is expected for an increased volume of patients to benefit from obesity services through implementation at organisation level.
6. The expected benefits for the partner organisation(s) on delivery of this project are:	Ability to offer weight management services to a wider number of patients improving equity of access to eligible NICE patients
7. The expected benefits for Lilly UK on delivery of this are:	<p>An understanding of the benefits of primary care-based weight management services in Greater Manchester which can be translated to learnings across the UK. Insights on the potential use of obesity licensed medicines in line with NICE guidelines.</p> <p>Publication of this project on Lilly UK corporate website and in the ABPI repository would demonstrate Lilly to be a valued partner to the NHS in innovation and may strengthen Lilly’s reputation.</p>